Research progress on the relationship between the metabolic score for insulin resistance and cardiovascular disease
-
摘要: 心血管疾病是全球范围内导致死亡和疾病负担的主要原因，涉及冠心病、高血压、心力衰竭、动脉粥样硬化等多种病理状态。随着心血管疾病发病率的增加，早期识别和精准评估心血管疾病风险变得尤为重要。胰岛素抵抗在心血管疾病的发生和进展中起着重要作用，成为心血管疾病的重要病理机制之一。胰岛素抵抗代谢评分作为一种新型胰岛素抵抗评估的简便指标，结合空腹血糖、甘油三酯、高密度脂蛋白胆固醇和体重指数等常规检测指标，有效反映了个体的代谢状态。近年来研究表明，胰岛素抵抗代谢评分在心血管疾病的预测中具有显著的临床价值，其不仅能够作为心血管疾病早期筛查和高危人群评估的重要工具，还能在个体化治疗和预防策略的制定中发挥重要作用。本文综述了胰岛素抵抗代谢评分在心血管疾病中的诊断及临床应用价值，探讨其未来在心血管疾病防治中的潜力和发展方向。Abstract: Cardiovascular diseases(CVD) are the leading cause of morbidity and mortality globally, encompassing a range of conditions including coronary artery disease, hypertension, heart failure, atherosclerosis, and other related pathologies. With the increasing prevalence of CVD, early identification and accurate risk assessment are critical for effective intervention. Insulin resistance plays a pivotal role in the pathogenesis and progression of CVD and has emerged as a key pathological mechanism in its development. The metabolic score for insulin resistance(METS-IR) is a novel, convenient, and non-invasive indicator for assessing insulin resistance, which integrates conventional clinical biomarkers, such as fasting blood glucose, triglycerides, high-density lipoprotein cholesterol, and body mass index, to provide a comprehensive measure of metabolic status. Recent studies have demonstrated that METS-IR holds significant predictive value for CVD. It serves not only as an essential tool for early screening and risk stratification in high-risk populations but also plays a critical role in the formulation of personalized therapeutic and preventive strategies. This review discusses the diagnostic and clinical applicability of METS-IR in CVD and explores its potential for advancing future prevention and treatment approaches in CVD.
-
-
[1] Bułdak Ł. Cardiovascular Diseases-A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies[J]. Int J Mol Sci, 2022, 23, 23(9): 4695.
[2] Lavie CJ. Progress in Cardiovascular Diseases Statistics[J]. Prog Cardiovasc Dis, 2022, 73: 94-95. doi: 10.1016/j.pcad.2022.08.005
[3] Tao LC, Xu JN, Wang TT, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations[J]. Cardiovasc Diabetol, 2022, 21(1): 68. doi: 10.1186/s12933-022-01511-x
[4] Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, et al. Diagnostic Accuracy of the Triglyceride and Glucose Index for Insulin Resistance: A Systematic Review[J]. Int J Endocrinol, 2020, 2020: 4678526.
[5] Zhou Z, Liu Q, Zheng M, et al. Comparative study on the predictive value of TG/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study[J]. Cardiovasc Diabetol, 2024, 23(1): 213. doi: 10.1186/s12933-024-02308-w
[6] Qian T, Sheng X, Shen P, et al. Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids[J]. Front Endocrinol(Lausanne), 2023, 14: 1224967. doi: 10.3389/fendo.2023.1224967
[7] Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes[J]. Eur J Endocrinol, 2018, 178(5): 533-544. doi: 10.1530/EJE-17-0883
[8] Widjaja NA, Irawan R, Hanindita MH, et al. METS-IR vs. HOMA-AD and Metabolic Syndrome in Obese Adolescents[J]. J Med Invest, 2023, 70(1.2): 7-16. doi: 10.2152/jmi.70.7
[9] Ma X, Ji B, Du W, et al. METS-IR, a Novel Simple Insulin Resistance Index, is Associated with NAFLD in Patients with Type 2 Diabetes Mellitus[J]. Diabetes Metab Syndr Obes, 2024, 17: 3481-3490. doi: 10.2147/DMSO.S476398
[10] Su X, Zhao C, Zhang X. Association between METS-IR and heart failure: a cross-sectional study[J]. Front Endocrinol(Lausanne), 2024, 15: 1416462. doi: 10.3389/fendo.2024.1416462
[11] Kosmas CE, Bousvarou MD, Kostara CE, et al. Insulin resistance and cardiovascular disease[J]. J Int Med Res, 2023, 51(3): 3000605231164548. doi: 10.1177/03000605231164548
[12] Yuan M, Li W, Zhu Y, et al. Asprosin: A Novel Player in Metabolic Diseases[J]. Front Endocrinol(Lausanne), 2020, 11: 64. doi: 10.3389/fendo.2020.00064
[13] Liu Y, Sun R, Lin X, et al. Procyanidins and its metabolites by gut microbiome improves insulin resistance in gestational diabetes mellitus mice model via regulating NF-κB and NLRP3 inflammasome pathway[J]. Biomed Pharmacother, 2022, 151: 113078. doi: 10.1016/j.biopha.2022.113078
[14] Di Meo S, Iossa S, Venditti P. Skeletal muscle insulin resistance: role of mitochondria and other ROS sources[J]. J Endocrinol, 2017, 233(1): R15-R42. doi: 10.1530/JOE-16-0598
[15] Duan M, Zhao X, Li S, et al. Metabolic score for insulin resistance(METS-IR)predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001-2018[J]. Cardiovasc Diabetol, 2024, 23(1): 243. doi: 10.1186/s12933-024-02334-8
[16] Polak M, Nowicki GJ, Chrzanowska-Wasik M, et al. Do sociodemographic and health predictors affect the non-insulin-based insulin resistance index? A cross-sectional study[J]. Adv Clin Exp Med, 2024 Nov 12. doi:
10.17219/acem/191200 . Epubaheadofprint.[17] Zhang L, Yu C, Wang T, et al. Association of the metabolic score for insulin resistance with cardiovascular diseases, cardiovascular and all-cause mortality in Chinese hypertensive population[J]. Front Endocrinol(Lausanne), 2024, 14: 1326436. doi: 10.3389/fendo.2023.1326436
[18] Virginia B, Francesca M, Marta B, et al. Metabolic Score for Insulin Resistance(METS-IR)and Circulating Cytokines in Older Persons: The Role of Gender and Body Mass Index[J]. Nutrients, 2022, 14(15): 3228. doi: 10.3390/nu14153228
[19] Tamehri Zadeh SS, Cheraghloo N, Masrouri S, et al. Association between metabolic score for insulin resistance and clinical outcomes: insights from the Tehran lipid and glucose study[J]. Nutr Metab(Lond), 2024, 21(1): 34.
[20] Wu Z, Cui H, Zhang Y, et al. The impact of the metabolic score for insulin resistance on cardiovascular disease: a 10-year follow-up cohort study[J]. J Endocrinol Invest, 2023, 46(3): 523-533.
[21] Li X, Wang J, Zhang M, et al. Biological aging mediates the associations of metabolic score for insulin resistance with all-cause and cardiovascular disease mortality among US adults: A nationwide cohort study[J]. Diabetes Obes Metab, 2024, 26(9): 3552-3564. doi: 10.1111/dom.15694
[22] Wang Z, Hui X, Huang X, et al. Relationship between a novel non-insulin-based metabolic score for insulin resistance(METS-IR)and coronary artery calcification[J]. BMC Endocr Disord, 2022, 22(1): 274. doi: 10.1186/s12902-022-01180-7
[23] Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, et al. Prediction of incident hypertension and arterial stiffness using the non-insulin-based metabolic score for insulin resistance(METS-IR)index[J]. J Clin Hypertens(Greenwich), 2019, 21(8): 1063-1070. doi: 10.1111/jch.13614
[24] Xu C, Song G, Hu D, et al. Association of METS-IR with incident hypertension in non-overweight adults based on a cohort study in Northeastern China[J]. Eur J Public Health, 2022, 32(6): 884-890. doi: 10.1093/eurpub/ckac140
[25] Lv D, Liu Z, Wu X, et al. Novel metabolic indicators and the risk of cardiovascular disease in patients with hypertension: A primary-care cohort study[J]. Nutr Metab Cardiovasc Dis, 2024 Sep 21: S0939-4753(24)00368-5. doi:
10.1016/j.numecd.2024.09.019 . Epubaheadofprint.[26] Rao K, Yang J, Wu M, et al. Association Between the Metabolic Score for Insulin Resistance and Hypertension in Adults: A Meta-Analysis[J]. Horm Metab Res, 2023, 55(4): 256-265. doi: 10.1055/a-2010-2452
[27] Chen L, Qian L, Liu Y. Association Between Different Insulin Resistance Indices and Heart Failure in US Adults With Diabetes Mellitus[J]. Ann Noninvasive Electrocardiol, 2024, 29(6): e70035. doi: 10.1111/anec.70035
[28] Xie Q, Liu C, Liu F, et al. Predictive Effect of Alternative Insulin Resistance Indexes on Adverse Cardiovascular Events in Patients with Metabolic Syndrome with Heart Failure[J]. Diabetes Metab Syndr Obes, 2024, 17: 2347-2356. doi: 10.2147/DMSO.S457598
[29] Zhou Y, Xie Y, Du L, et al. Metabolic score for insulin resistance as a predictor of mortality in heart failure with preserved ejection fraction: results from a multicenter cohort study[J]. Diabetol Metab Syndr, 2024, 16(1): 220. doi: 10.1186/s13098-024-01463-0
[30] Lembo M, Trimarco V, Manzi MV, et al. Determinants of improvement of left ventricular mechano-energetic efficiency in hypertensive patients[J]. Front Cardiovasc Med, 2022, 9: 977657. doi: 10.3389/fcvm.2022.977657
[31] Zhang X, Liu F, Li W, et al. Metabolic Score for Insulin Resistance(METS-IR) Predicts Adverse Cardiovascular Events in Patients with Type 2 Diabetes and Ischemic Cardiomyopathy[J]. Diabetes Metab Syndr Obes, 2023, 16: 1283-1295. doi: 10.2147/DMSO.S404878
[32] Shenouda R, Vancheri S, Maria Bassi E, et al. The relationship between carotid and coronary calcification in patients with coronary artery disease[J]. Clin Physiol Funct Imaging, 2021, 41(3): 271-280. doi: 10.1111/cpf.12694
[33] Shamaki GR, Markson F, Soji-Ayoade D, et al. Peripheral Artery Disease: A Comprehensive Updated Review[J]. Curr Probl Cardiol, 2022, 47(11): 101082. doi: 10.1016/j.cpcardiol.2021.101082
[34] Andreucci M, Rigiracciolo DC, Bracale UM, et al. Assessment of androgen receptor, IGF-IR and insulin receptor expression in male patients with severe peripheral artery disease[J]. Heliyon, 2022, 8(1): e08756. doi: 10.1016/j.heliyon.2022.e08756
[35] Liu G. Association between the metabolic score for insulin resistance(METS-IR)and arterial stiffness among health check-up population in Japan: a retrospective cross-sectional study[J]. Front Endocrinol(Lausanne), 2024, 14: 1308719. doi: 10.3389/fendo.2023.1308719
[36] Mestre Font M, Busquets-Cortés C, Ramírez-Manent JI, et al. Influence of Sociodemographic Variables and Healthy Habits on the Values of Insulin Resistance Indicators in 386, 924 Spanish Workers[J]. Nutrients, 2023, 15(24): 5122. doi: 10.3390/nu15245122
[37] Lee HY, Sakuma I, Ihm SH, et al. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease[J]. Circ J, 2014, 78(2): 281-287. doi: 10.1253/circj.CJ-13-1494
[38] Zhao H, Xing C, Zhang J, et al. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis[J]. Reprod Health, 2021, 18(1): 171. doi: 10.1186/s12978-021-01207-7
[39] Vargas-Vázquez A, Fermín-Martínez CA, Antonio-Villa NE, et al. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes[J]. Atherosclerosis, 2024, 395: 117508. doi: 10.1016/j.atherosclerosis.2024.117508
-
计量
- 文章访问数: 654
- 施引文献: 0
下载: